Cargando…

Key issues for establishing a robotics laboratory in the pharmaceutical industry

The Analytical Research and Development Department of Bristol-Myers Squibb has a laboratory dedicated to robotic analysis of solid dose forms. It consists of eight individuals responsible for nine robotic systems. The laboratory is dedicated to the support of Phase III stability studies that require...

Descripción completa

Detalles Bibliográficos
Autor principal: Conder, Steve
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 1994
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2548047/
https://www.ncbi.nlm.nih.gov/pubmed/18924996
http://dx.doi.org/10.1155/S1463924694000106
_version_ 1782159389978787840
author Conder, Steve
author_facet Conder, Steve
author_sort Conder, Steve
collection PubMed
description The Analytical Research and Development Department of Bristol-Myers Squibb has a laboratory dedicated to robotic analysis of solid dose forms. It consists of eight individuals responsible for nine robotic systems. The laboratory is dedicated to the support of Phase III stability studies that require dissolution, potency, content. uniformity and Karl Fischer moisture assays. The group performs about 15000 assays a year for approximately six long-term stability programs. The key issues for success were personnel selection, methods development (methods transfer), routine assay support, documentation, validation, training and support services. This paper discusses the establishment of the laboratory and the future issues important to continued success.
format Text
id pubmed-2548047
institution National Center for Biotechnology Information
language English
publishDate 1994
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-25480472008-10-16 Key issues for establishing a robotics laboratory in the pharmaceutical industry Conder, Steve J Automat Chem Research Article The Analytical Research and Development Department of Bristol-Myers Squibb has a laboratory dedicated to robotic analysis of solid dose forms. It consists of eight individuals responsible for nine robotic systems. The laboratory is dedicated to the support of Phase III stability studies that require dissolution, potency, content. uniformity and Karl Fischer moisture assays. The group performs about 15000 assays a year for approximately six long-term stability programs. The key issues for success were personnel selection, methods development (methods transfer), routine assay support, documentation, validation, training and support services. This paper discusses the establishment of the laboratory and the future issues important to continued success. Hindawi Publishing Corporation 1994 /pmc/articles/PMC2548047/ /pubmed/18924996 http://dx.doi.org/10.1155/S1463924694000106 Text en Copyright © 1994 Hindawi Publishing Corporation. http://creativecommons.org/licenses/by/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Conder, Steve
Key issues for establishing a robotics laboratory in the pharmaceutical industry
title Key issues for establishing a robotics laboratory in the pharmaceutical industry
title_full Key issues for establishing a robotics laboratory in the pharmaceutical industry
title_fullStr Key issues for establishing a robotics laboratory in the pharmaceutical industry
title_full_unstemmed Key issues for establishing a robotics laboratory in the pharmaceutical industry
title_short Key issues for establishing a robotics laboratory in the pharmaceutical industry
title_sort key issues for establishing a robotics laboratory in the pharmaceutical industry
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2548047/
https://www.ncbi.nlm.nih.gov/pubmed/18924996
http://dx.doi.org/10.1155/S1463924694000106
work_keys_str_mv AT condersteve keyissuesforestablishingaroboticslaboratoryinthepharmaceuticalindustry